Generic Katerzia Availability
Last updated on Jan 8, 2025.
Katerzia is a brand name of amlodipine, approved by the FDA in the following formulation(s):
KATERZIA (amlodipine benzoate - suspension;oral)
-
Manufacturer: AZURITY
Approval date: July 8, 2019
Strength(s): EQ 1MG BASE/ML [RLD]
Has a generic version of Katerzia been approved?
No. There is currently no therapeutically equivalent version of Katerzia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Katerzia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Amlodipine formulations
Patent 10,695,329
Issued: June 30, 2020
Inventor(s): Brauer Scott & Mosher Gerold L.
Assignee(s): SILVERGATE PHARMACEUTICALS, INC.Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
Patent expiration dates:
- October 16, 2037✓
- October 16, 2037
-
Amlodipine formulations
Patent 10,799,453
Issued: October 13, 2020
Inventor(s): Brauer Scott & Mosher Gerold L.
Assignee(s): Silvergate Pharmaceuticals, Inc.Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
Patent expiration dates:
- April 11, 2039✓
- April 11, 2039
-
Amlodipine formulations
Patent 10,894,039
Issued: January 19, 2021
Inventor(s): Brauer Scott & Mosher Gerold L.
Assignee(s): Silvergate Pharmaceuticals, Inc.Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037✓
- October 6, 2037
-
Amlodipine formulations
Patent 10,952,998
Issued: March 23, 2021
Inventor(s): Brauer Scott & Mosher Gerold L.
Assignee(s): Silvergate Pharmaceuticals, Inc.Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037
-
Amlodipine formulations
Patent 10,959,991
Issued: March 30, 2021
Inventor(s): Brauer Scott & Mosher Gerold L.
Assignee(s): Silvergate Pharmaceuticals, Inc.Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037✓
- October 6, 2037
-
Patent 11,364,230
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037
-
Patent 11,471,409
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037✓
- October 6, 2037
-
Patent 11,484,498
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037
-
Patent 11,701,326
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037
-
Patent 11,918,685
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037✓
- October 6, 2037
-
Patent 12,053,461
Patent expiration dates:
- October 6, 2037✓
- October 6, 2037
More about Katerzia (amlodipine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: calcium channel blockers
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.